Research Article
Modeling of Non-Small Cell Lung Cancer Volume Changes during CT-Based Image Guided Radiotherapy: Patterns Observed and Clinical Implications
Table 1
Individual patient, tumor, treatment, and tumor response characteristics. Patient IDs starting with an “L” had a long RT course while those starting with an “S” had a short one.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Abbreviations: ID: identifier; M: male; F: female; Fx.: daily fraction dose; BED10: biologically effective dose, / ratio of 10; SCCA: squamous cell carcinoma; ACA: adenocarcinoma; NSCLC: nonsmall cell lung cancer, not otherwise specified; RT: radiotherapy; chemo: chemotherapy. *Three cycles of neoadjuvant paclitaxel (200 mg/m2) and carboplatin (AUC 5). †Clinical history consistent with metastatic breast adenocarcinoma. ‡Patient completed chemotherapy for breast cancer 5 months prior to radiotherapy. Biopsy proven recurrence after receiving 50 Gy in 2.5 Gy fractions. Received neoadjuvant, concurrent, and adjuvant erlotinib (150 mg) and bevacizumab (15 mg/kg) for this course of RT. #Atypical cells suspicious for malignancy; serial CTs, PET/CT SUV 2.5, and clinical history consistent with primary lung malignancy. |